Compare ZVRA & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZVRA | GUG |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.2M | 509.2M |
| IPO Year | 2015 | 2021 |
| Metric | ZVRA | GUG |
|---|---|---|
| Price | $11.88 | $15.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 105.1K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 159.21 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $106,470,000.00 | N/A |
| Revenue This Year | $37.27 | N/A |
| Revenue Next Year | $53.42 | N/A |
| P/E Ratio | $16.04 | ★ N/A |
| Revenue Growth | ★ 350.91 | N/A |
| 52 Week Low | $7.16 | $14.66 |
| 52 Week High | $15.04 | $16.46 |
| Indicator | ZVRA | GUG |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 40.58 |
| Support Level | $8.15 | $14.75 |
| Resistance Level | $12.19 | $16.17 |
| Average True Range (ATR) | 0.45 | 0.26 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 70.49 | 38.36 |
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.